Clinical Trials
11 trialsNCT03347617 2025-09-09
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT02208362 2025-09-03
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03137888 2025-08-03
Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
Emory University
Phase 2 Completed
NCT03778294 2025-07-03
18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy
Mayo Clinic
Phase 2 Completed
NCT02663271 2022-06-23
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
University of Florida
Phase 2 Terminated
NCT02120287 2019-05-07
Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme
University of Pittsburgh
Phase 2 Completed
NCT00902577 2019-04-08
MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT01342757 2018-01-29
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
National Cancer Institute (NCI)
Phase NA Completed
NCT02175745 2017-03-20
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
Stanford University
Phase NA Terminated
NCT00095940 2014-05-23
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00412542 2012-02-28
Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
M.D. Anderson Cancer Center
Phase 2 Completed